



## NEWS RELEASE

### FOR IMMEDIATE RELEASE

#### COLORCON COMMUNICATIONS CONTACT:

Deborah J. Taylor

Director - Global Market Communications

Phone: +44-1322-627234

[dtaylor@colorcon.com](mailto:dtaylor@colorcon.com)

#### **Colorcon, Inc. Launches Acryl-EZE II to Extend pH Range of Enteric Coatings for Pharmaceutical Use**

Harleysville, Pennsylvania, USA, 16th July 2020 Colorcon, a world leader in the development and supply of film coating systems and excipients, today announces the launch of Acryl-EZE II which extends the pH range covered by its enteric coatings.

Delayed release oral solid dosage forms developed with enteric coating provide either protection of the gastric mucosa from irritating actives or protection of drugs unstable in gastric fluids. Applications include tablets and multiparticulate dosages for a range of drug products, including proton pump inhibitors (PPI) which are commonly used to treat acid reflux and ulcers of the stomach and the duodenum.

Acryl-EZE II extends Colorcon's line of aqueous enteric systems to provide specific applications for tablets and multiparticulate dosage forms with enhanced enteric protection up to a challenging level of pH 5.0 seen with patients taking PPIs, or when tested under fed conditions.

Kelly Boyer, General Manager Film Coatings explains: "This extension to the Acryl-EZE portfolio of products represents an advance in delayed release coating technology to provide the pharmaceutical industry with added convenience for enteric coating. Acryl-EZE formulations provide significant time savings in both development and production; while enabling targeted drug delivery across a wide pH range".

Dr. Ali Rajabi-Siahboomi adds: "The formulation of enteric coatings is challenging; requiring multiple ingredients and process steps. Through Colorcon's coating technology, this new Acryl-EZE II formulation provides simplified preparation and use, with enhanced protection up to pH 5.0 through the addition of a special top-coat. Coating performance has been validated through a human volunteer study in the most challenging fed state conditions, confirming bioavailability and *in-vivo* performance."



This latest innovation demonstrates Colorcon's leadership in bringing to market film coating systems with enhanced functionality along with improved convenience, manufacturing efficiency, cost savings and dependable performance for the pharmaceutical industry.

### **Company Information**

Colorcon is a world leader in the development, supply and technical support of specialty ingredients; formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complemented by our extensive application data and value-added services to support all phases of solid oral dose design, development and manufacture. Our focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical design and development partner. That reputation is based on superior product quality, unparalleled technical support, extensive regulatory assistance and reliable supply from multiple locations. Colorcon has 11 manufacturing facilities, 22 technical service laboratories globally and more than 1200 employees exclusively dedicated to its customer base.

For more information, visit [www.colorcon.com](http://www.colorcon.com)